Serum prostate-specific antigen levels reflect the androgen milieu in patients with localized prostate cancer receiving androgen deprivation therapy: Tumor malignant potential and androgen milieu

Prostate

Volumn 70, Issue 13, 2010, Pages 1395-1401

  Takizawa, Itsuhiro ^a   Nishiyama, Tsutomu ^a   Hara, Noboru ^a   Isahaya, Etsuko ^a   Hoshii, Tatsuhiko ^a   Takahashi, Kota ^a  

^a NIIGATA UNIVERSITY GRADUATE SCHOOL OF MEDICAL AND DENTAL SCIENCES   (Japan)

Author keywords

Androgen deprivation therapy; Androgen milieu; Prostate specific antigen; Testosterone

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTENEDIONE; FLUTAMIDE; FOLLITROPIN; GOSERELIN; LUTEINIZING HORMONE; PRASTERONE SULFATE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROSTENEDIONE BLOOD LEVEL; ARTICLE; BLOOD SAMPLING; CANCER CONTROL; CANCER LOCALIZATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG WITHDRAWAL; GLEASON SCORE; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; SIDE EFFECT; TESTOSTERONE BLOOD LEVEL; BLOOD; CHI SQUARE DISTRIBUTION; MIDDLE AGED; PROSTATE TUMOR; TREATMENT OUTCOME;

AGED; ANDROGENS; ANTINEOPLASTIC AGENTS, HORMONAL; CHI-SQUARE DISTRIBUTION; FLUTAMIDE; GOSERELIN; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77956624140     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21174     Document Type: Article

References (32)

1. Michaelson MD, Cotter SE, Gargollo PC, Zietman AL, Dahl DM, Smith MR,. Management of complications of prostate cancer treatment. CA Cancer J Clin 2008; 58: 196 -213.
2. Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM,. Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 6410 -6417.
3. Wirth M, Tyrrell C, Wallace M, Delaere KP, Sanchez-Chapado M, Ramon J, Hetherington J, Pina F, Heynes CF, Borchers TM, Morris T, Stone A,. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression. Urology 2001; 58: 146 -151.
4. Moul JW, Wu H, Sun L, McLeod DG, Amling C, Donahue T, Kusuda L, Sexton W, O'Reilly K, Hernandez J, Chung A, Soderdahl D,. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 2004; 171: 1141 -1147.
5. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. Br J Urol 1997; 79: 235 -246.
6. Nishiyama T, Ishizaki F, Anraku T, Shimura H, Takahashi K,. The influence of androgen deprivation therapy on metabolism in patients with prostate cancer. J Clin Endocrinol Metab 2005; 90: 657 -660.
7. Isahaya E, Hara N, Nishiyama T, Hoshii T, Takizawa I, Takahashi K,. Bone metabolic disorder in patients with prostate cancer receiving androgen deprivation therapy (ADT): Impact of ADT on the growth hormone/insulin-like growth factor-1/parathyroid hormone axis. Prostate 2010; 70: 155 -161.
8. Hara N, Nishiyama T, Takizawa I, Saito T, Kitamura Y, Takahashi K,. Decline of the red blood cell count in patients receiving androgen deprivation therapy (ADT) for localized prostate cancer: Impact of ADT on insulin-like growth factor-1 and erythropoiesis. Urology 2010; [Epub ahead of print].
9. Choo R, Klotz L, Danjoux C, Morton GC, DeBoer G, Szumacher E, Fleshner N, Bunting P, Hruby G,. Feasibility study: Watchful waiting for localized low to intermediate grade prostate carcinoma with selective delayed intervention based on prostate specific antigen, histological and/or clinical progression. J Urol 2002; 167: 1664 -1669.
10. Maatman TJ, Gupta MK, Montie JE,. Effectiveness of castration versus intravenous estrogen therapy in producing rapid endocrine control of metastatic cancer of the prostate. J Urol 1985; 133: 620 -621.
11. Tammela T,. Endocrine treatment of prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 287 -295.
12. Oefelein MG, Feng A, Scolieri MJ, Ricchiutti D, Resnick MI,. Reassessment of the definition of castrate levels of testosterone: Implications for clinical decision making. Urology 2000; 56: 1021 -1024.
13. Morote J, Planas J, Salvador C, Raventós CX, Catalan R, Reventós J,. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy. BJU Int 2009; 103: 332 -335.
14. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J,. Long-term survival among men with conservatively treated localized prostate cancer. JAMA 1995; 274: 626 -631.
15. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD,. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277: 1445 -1451.
16. Chan TY, Partin AW, Walsh PC, Epstein JI,. Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. Urology 2000; 56: 823 -827.
17. Herman CM, Kattan MW, Ohori M, Scardino PT, Wheeler TM, Primary Gleason pattern as a predictor of disease progression in Gleason score 7 prostate cancer: A multivariate analysis of 823 men treated with radical prostatectomy. Am J Surg Pathol 2001; 25: 657 -660.
18. Nishiyama T, Hashimoto Y, Takahashi K,. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 2004; 10: 7121 -7126.
19. Nishiyama T, Ikarashi T, Hashimoto Y, Wako K, Takahashi K,. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J Urol 2007; 178: 1282 -1288.
20. Endogenous Hormones and Prostate Cancer Collaborative Group, Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: A collaborative analysis of 18 prospective studies. J Natl Cancer Inst 2008; 100: 170 -183.
21. Morgentaler A,. Testosterone replacement therapy and prostate cancer. Urol Clin North Am 2007; 34: 555 -563.
22. Morgentaler A, Traish AM,. Shifting the paradigm of testosterone and prostate cancer: The saturation model and the limits of androgen-dependent growth. Eur Urol 2009; 55: 310 -320.
23. Balk SP, Ko YJ, Bubley GJ,. Biology of prostate-specific antigen. J Clin Oncol 2003; 21: 383 -391.
24. Hoffman MA, DeWolf WC, Morgentaler A,. Is low serum free testosterone a marker for high grade prostate cancer? J Urol 2000; 163: 824 -827.
25. Schatzl G, Madersbacher S, Thurridl T, Waldmüller J, Kramer G, Haitel A, Marberger M,. High-grade prostate cancer is associated with low serum testosterone levels. Prostate 2001; 47: 52 -58.
26. Massengill JC, Sun L, Moul JW, Wu H, McLeod DG, Amling C, Lance R, Foley J, Sexton W, Kusuda L, Chung A, Soderdahl D, Donahue T,. Pretreatment total testosterone level predicts pathological stage in patients with localized prostate cancer treated with radical prostatectomy. J Urol 2003; 169: 1670 -1675.
27. Imamoto T, Suzuki H, Akakura K, Komiya A, Nakamachi H, Ichikawa T, Igarashi T, Ito H,. Pretreatment serum level of testosterone as a prognostic factor in Japanese men with hormonally treated stage D2 prostate cancer. Endocr J 2001; 48: 573 -578.
28. Chodak GW, Vogelzang NJ, Caplan RJ, Soloway M, Smith JA,. Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group. JAMA 1991; 265: 618 -621.
29. Rhoden EL, Riedner CE, Morgentaler A,. The ratio of serum testosterone-to-prostate specific antigen predicts prostate cancer in hypogonadal men. J Urol 2008; 179: 1741 -1745.
30. Miller LR, Partin AW, Chan DW, Bruzek DJ, Dobs AS, Epstein JI, Walsh PC,. Influence of radical prostatectomy on serum hormone levels. J Urol 1998; 160: 449 -453.
31. Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K, Komiya A, Naya Y, Shiraishi T, Ichikawa T,. Does presence of prostate cancer affect serum testosterone levels in clinically localized prostate cancer patients? Prostate Cancer Prostatic Dis 2009; 12: 78 -82.
32. Zhang PL, Rosen S, Veeramachaneni R, Kao J, DeWolf WC, Bubley G,. Association between prostate cancer and serum testosterone levels. Prostate 2002; 53: 179 -182.